Highlights of dry eye Phase 2 clinical study revealed

Article

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution. According to the company, the study showed improvements in conjunctival and corneal staining as well as alleviating other bothersome ocular symptoms. Improvements in signs and symptoms of dry eye disease were reported to continue for 10 days after discontinuing treatment.

The phase 2 study enrolled 38 patients with signs and symptoms consistent with dry eye and monitored the effects that the solution had on these. Patients received the solution under normal conditions in both eyes, twice a day for 42 days. Conjunctival staining, monitored by the Lissamine Green test, was shown to have improved compared to the baseline, as was corneal staining (monitored by the Fluorescein test). Additionally, improvements in subjective symptoms were reported, based on results from the Ocular Surface Disease Index as well as in patients' most bothersome ocular symptoms.

These results were presented during poster sessions at the 6th International conference on Tear film & Ocular Surface in Florence, Italy.

The company has now announced that it will begin a Phase 3 clinical study programme later this year and expect to report initial results in the middle of 2011.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.